IPOL® is recommended for routine polio immunization in the US1... An adult traveler is considered fully immunized if he or she has received a primary series of at least 3 doses of IPOL® before entry into a polioendemic area1 Is recommended by the American Academy of Pediatrics, the Advisory Committee on Immunization Practices, and the American Academy of Family Physicians2-4 Has been proven to confer herd immunity against wild-type polio5-7 Protects against wild-type polio without the risk of vaccine-associated paralytic polio (VAPP) for patients and their contacts2,3 Recommended adult dosing 2 doses administered at intervals of 4 to 8 weeks Third dose administered 6 to 12 months after the second Intramuscular administration Accelerated dosing for time constraints1 If more than 8 weeks are available:   3 doses of IPV,* 4 weeks apart If 4 to 8 weeks are available:   2 doses at least 4 weeks apart If less than 4 weeks:   a single dose *IPV= Inactivated Poliovirus Vaccine Safety Information IPOL® is indicated for the active immunization of infants, children, and adults for the prevention of poliomyelitis. Local adverse reactions may include fever, irritability, drowsiness, anorexia, and crying. Other local and systemic adverse reactions may occur. IPOL® is contraindicated in persons with a hypersensitivity to any component of the vaccine. As with any vaccine, vaccination with IPOL® may not protect 100% of susceptible individuals. Click here to view full Prescribing Information for IPOL®. IPOL® is manufactured by Aventis Pasteur SA and distributed by Aventis Pasteur Inc. REFERENCES: 1. Centers for Disease and Control (CDC). Health Information for International Travel 2001-2002. Atlanta, GA: US Dept of Health and Human Services; 2001:131-133. 2. Recommendations of the Advisory Committee on Immunization Practices: revised recommendations for routine poliomyelitis vaccination. MMWR Morb Mortal Wkly Rep. 1999;48:590. 3. American Academy of Pediatrics: Committee on Infectious Diseases. Prevention of poliomyelitis: recommendations for use of only inactivated polio virus vaccine for routine immunization. Pediatrics. 1999;104:1404-1406. 4. American Academy of Pediatrics, Committee on Infectious Diseases. Recommended childhood immunization schedule—United States, 2002. Pediatrics. 2002;109:162-164. 5. Strebel PM, Sutter RW, Cochi SL, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis. 1992;14:568-579. 6. Plotkin SA. Inactivated polio vaccine for the United States: a missed vaccination opportunity. Pediatr Infect Dis J. 1995;14:835-840. 7. Salk D. Herd effect and virus eradication with use of killed poliovirus vaccine. Dev Biol Stand. 1981;47:247-255.